Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to... see more

Recent & Breaking News (NDAQ:MCRB)

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire 7 days ago

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

GlobeNewswire 13 days ago

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

GlobeNewswire October 29, 2025

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

GlobeNewswire October 14, 2025

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

GlobeNewswire September 23, 2025

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire August 27, 2025

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire August 6, 2025

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

GlobeNewswire July 22, 2025

Seres Therapeutics Announces Leadership Transition

GlobeNewswire July 22, 2025

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

GlobeNewswire May 27, 2025

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire May 7, 2025

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

GlobeNewswire April 29, 2025

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

GlobeNewswire April 23, 2025

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire March 13, 2025

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

GlobeNewswire March 4, 2025

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

GlobeNewswire March 3, 2025

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

GlobeNewswire January 16, 2025

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

GlobeNewswire January 9, 2025

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

GlobeNewswire December 16, 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

GlobeNewswire December 9, 2024